Clinical formulations of anti-TIGIT antibodies

The present disclosure relates to pharmaceutical formulations of anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies. The present disclosure also relates to articles of manufacture comprising such pharmaceutical formulation...

Full description

Saved in:
Bibliographic Details
Main Authors TSCHUDI, KATHERINE LAURA, SUHLING, ROBYN MARIAH, WOYS, ANN MARIE, SANE, RUCHA SUDHAKAR, SHIEH, IAN CHUNG-TI, CHAN, HUI MIN PHYLLIS, ROONEY, ISABELLE ANNE, WEN, XIAOHUI
Format Patent
LanguageChinese
English
Published 01.08.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to pharmaceutical formulations of anti-TIGIT monoclonal antibodies that are suitable for co-administration or co-formulation with anti-PD-L1 monoclonal antibodies. The present disclosure also relates to articles of manufacture comprising such pharmaceutical formulations and methods of treating cancer using the pharmaceutical formulations and to use of the pharmaceutical formulations for the treatment of cancer or the manufacture of a medicament for treating cancer. The present disclosure also relates to articles of manufacture comprising single doses of anti-TIGIT monoclonal antibodies or both anti-TIGIT and anti-PD-L1 monoclonal antibodies and methods of treating cancer using such articles of manufacture and the formulations contained therein.
Bibliography:Application Number: TW20220149551